Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Bristol-Myers Squibb
Age
18–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with Type 2 diabetes mellitus with inadequate glycemic control on diet and exercise. HbA1c \>= 7% and \<=10%.
Patient either has not been previously treated with antihyperglycemic medication or has been treated for \<30 days since diagnosis and has received less than 3 consecutive doses or 7 non-consecutive doses in the last 30 days.
C-peptide \> 1.0 ng/ml
Body Mass Index \<= 40 kg/m2
Serum creatinine \< 1.5 mg/dL for men or \< 1.4 mg/dL for women.
No overt proteinuria (microalbumin/creatinine ratio must be \<300 mg/g
You may not be if
Unstable renal disease
Patients with significant liver disease including chronic active hepatitis
Within the last 6 months has had any of the following cardiovascular event: myocardial infarction, unstable angina, unstable CHF,NYHA Class III or IV CHF, TIA, unstable arrhythmia or cardiac revascularization surgery.
Subjects with clinically significant anemia
Clareo Health | A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
